Febrile Neutropenia Market, By Treatment Type (Empirical Antibiotic Therapy, Supportive Care, and Targeted Antibiotic Therapy), By Etiology, By Diagnostic Methods, By Risk Factors, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4570
|
Published Date
December 2025
|
Pages
386
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
The Febrile Neutropenia Market size was valued at US$ 11,123.54 Million in 2024, expanding at a CAGR of 4.0% from 2025 to 2032.
The Febrile Neutropenia market encompasses therapies, biologics, and supportive care solutions designed to manage fever associated with low neutrophil counts in cancer patients undergoing chemotherapy. Market growth is primarily driven by the rising global cancer burden, which increases the number of immunocompromised patients at risk for severe infections. A notable industry trend is the rapid adoption of long-acting granulocyte-colony stimulating factor (G-CSF) therapies and biosimilars, which enhance patient convenience, reduce hospitalizations, and improve overall outcomes. However, high treatment costs and limited access to advanced biologics in low- and middle-income countries continue to pose significant adoption challenges. Despite these barriers, substantial opportunities exist in precision medicine, where biomarkers and AI-powered risk prediction tools enable personalized neutropenia management. As oncology pipelines expand and healthcare systems increasingly prioritize infection prevention, the febrile neutropenia market is shifting toward innovative, patient-centric therapeutic solutions. Globally, cancer continues to be a major public health challenge, with an estimated 20 million new cases and 9.7 million cancerrelated deaths reported worldwide in 2022, and projections indicating new cancer cases could reach over 35 million by 2050 due to population growth and aging populations.
Febrile Neutropenia Market- Market Dynamics
Rising Cancer Incidence Driving Robust Growth in the Febrile Neutropenia Market
Rising global cancer incidence is a key driver of the febrile neutropenia market. As chemotherapy treatments increase, the risk of febrile neutropenia among patients also rises, creating higher demand for preventive and therapeutic interventions. For instance, the American Cancer Society reported in January 2022 that the United States recorded approximately 1.9 million new cancer cases and over 609,000 cancer-related deaths, with lung, breast, prostate, and colorectal cancers accounting for 43% of all diagnoses. The expanding population of immunocompromised patients worldwide underscores the critical need for effective febrile neutropenia management. Consequently, demand for biologics, long-acting G-CSF therapies, and advanced supportive care solutions is expected to grow steadily in the coming years.
Febrile Neutropenia Market- Segmentation Analysis:
The worldwide market is segmented on the basis of Treatment Type, Etiology, Diagnostic Methods, Risk Factors, End User, and Region.
Based on risk factors, chemotherapy-induced neutropenia continues to dominate the febrile neutropenia market due to the widespread use of chemotherapy regimens that significantly suppress immune function and increase infection risks in cancer patients. This segment benefits from ongoing advancements in supportive care, with biopharmaceutical companies actively developing long-acting G-CSF therapies that improve treatment continuity and reduce hospitalization. Government health statistics highlight the prevalence and clinical impact of this condition; for example, the U.S. National Cancer Institute (NCI) reported that over 60% of patients receiving myelosuppressive chemotherapy experience some degree of neutropenia, emphasizing the need for effective supportive therapies. In response to this demand, on May 16, 2023, Amneal Pharmaceuticals introduced FYLNETRA (pegfilgrastim pbbk), a biosimilar to Neulasta, in a pre-filled single-dose syringe, providing an accessible treatment option for patients at high risk of febrile neutropenia.
Based on end user, hospitals account for the largest segment due to their advanced healthcare infrastructure, specialized oncology departments, and capacity to manage complex treatment protocols. The high volume of cancer admissions, particularly among chemotherapy patients at risk of neutropenia, reinforces hospitals’ central role in this market. Hospitals are equipped with specialized monitoring systems, multidisciplinary expertise, and 24-hour care capabilities to administer biologics and supportive treatments efficiently. Government healthcare data further supports this trend; for instance, the U.S. Centers for Medicare & Medicaid Services (CMS) reported that over 70% of inpatient chemotherapy administrations in 2023 occurred in hospital settings, highlighting hospitals’ critical role in managing acute neutropenia. Complementary care models are also emerging, such as digital and home-based platforms. For example, in 2022, CVS Health dispensed over 40,000 neutropenia prescriptions through its digital pharmacy platform, demonstrating the growing integration of outpatient and telehealth services in supporting hospital-based treatment pathways.
Febrile Neutropenia Market- Geographical Insights
North America leads the febrile neutropenia market, supported by advanced healthcare infrastructure, high cancer prevalence, and robust pharmaceutical and biotechnology sectors. The United States, in particular, dominates the regional market due to the presence of major pharmaceutical companies, extensive R&D activities, and favorable healthcare policies that facilitate the adoption of innovative therapies. Meanwhile, the Middle East and Africa (MEA) region accounts for approximately 5% of the global market, driven by rising cancer incidence, improving healthcare infrastructure, and increasing awareness among healthcare professionals. Regulatory frameworks in these regions are evolving to support the introduction of new treatments, further enabling market growth.
United States Febrile Neutropenia Market – Country Insights
The U.S. market benefits from a high concentration of pharmaceutical and medical device companies actively involved in clinical trials, fostering the development of novel therapeutics and alternative treatment options. Regulatory approvals by the U.S. Food and Drug Administration (FDA) have been steadily increasing, facilitating faster market adoption. For example, on September 9, 2022, Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on targeted oncology therapies, received FDA approval for ROLVEDON (eflapegrastim-nst) injection to reduce the incidence of infections associated with febrile neutropenia. Such advancements underscore the United States’ leadership in developing and adopting innovative solutions for febrile neutropenia management.
Febrile Neutropenia Market- Competitive Landscape:
The Febrile Neutropenia Market is characterized by intense competition, driven by the rising incidence of cancer and the resulting increase in chemotherapy treatments. Key players such as Amgen Inc., Celgene Corporation, Roche Holding AG, and Bristol-Myers Squibb Company leverage diverse product portfolios and innovative capabilities to strengthen their market positions. Amgen (US) focuses on enhancing therapeutic offerings through ongoing research and development, while Roche (Switzerland) emphasizes personalized medicine and targeted therapies. Bristol-Myers Squibb (US) pursues strategic partnerships to expand its pipeline, reflecting a broader trend of collaborative innovation. Together, these strategies foster a competitive landscape increasingly reliant on technological advancements, strategic alliances, and patient-centric solutions.
Recent Developments:
- In August 2025, Roche announced a collaboration with a leading biotechnology company to develop a novel febrile neutropenia treatment, with clinical trials scheduled to begin in early 2026. This partnership underscores Roche’s commitment to innovation and addressing unmet medical needs in oncology, while enhancing its potential market share in the febrile neutropenia segment.
- In September 2025, Amgen launched a digital platform designed to improve patient engagement and treatment adherence for febrile neutropenia. This initiative highlights Amgen’s focus on digital transformation and patient-centered care, strengthening its competitive edge and fostering closer relationships with healthcare providers and patients.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FEBRILE NEUTROPENIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Amgen Inc.
- Sanofi S.A.
- Bayer AG
- Biogen Inc.
- Ono Pharmaceutical Co., Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Johnson & Johnson
- AstraZeneca plc
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Celgene Corporation
- Roche Holding AG
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Ipsen S.A.
- Others
GLOBAL FEBRILE NEUTROPENIA MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032
- Empirical Antibiotic Therapy
- Supportive Care
- Targeted Antibiotic Therapy
GLOBAL FEBRILE NEUTROPENIA MARKET, BY ETIOLOGY- MARKET ANALYSIS, 2019 - 2032
- Fungal Infections
- Gram-Negative Bacteria
- Gram-Positive Bacteria
- Viral Infections
GLOBAL FEBRILE NEUTROPENIA MARKET, BY DIAGNOSTIC METHODS- MARKET ANALYSIS, 2019 - 2032
- Blood Cultures
- Bone Marrow Aspiration
- Imaging Tests
GLOBAL FEBRILE NEUTROPENIA MARKET, BY RISK FACTORS- MARKET ANALYSIS, 2019 - 2032
- Transplant-Related Neutropenia
- Chemotherapy-Induced Neutropenia
- Genetic Disorders
GLOBAL FEBRILE NEUTROPENIA MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Others
GLOBAL FEBRILE NEUTROPENIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Febrile Neutropenia Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Febrile Neutropenia Market Snippet by Treatment Type
2.1.2. Febrile Neutropenia Market Snippet by Etiology
2.1.3. Febrile Neutropenia Market Snippet by Diagnostic Methods
2.1.4. Febrile Neutropenia Market Snippet by Risk Factors
2.1.5. Febrile Neutropenia Market Snippet by End User
2.1.6. Febrile Neutropenia Market Snippet by Country
2.1.7. Febrile Neutropenia Market Snippet by Region
2.2. Competitive Insights
3. Febrile Neutropenia Key Market Trends
3.1. Febrile Neutropenia Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Febrile Neutropenia Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Febrile Neutropenia Market Opportunities
3.4. Febrile Neutropenia Market Future Trends
4. Febrile Neutropenia Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Febrile Neutropenia Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Febrile Neutropenia Market Landscape
6.1. Febrile Neutropenia Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Febrile Neutropenia Market – By Treatment Type
7.1. Overview
7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
7.1.2. Empirical Antibiotic Therapy
7.1.3. Supportive Care
7.1.4. Targeted Antibiotic Therapy
8. Febrile Neutropenia Market – By Etiology
8.1. Overview
8.1.1. Segment Share Analysis, By Etiology, 2024 & 2032 (%)
8.1.2. Fungal Infections
8.1.3. Gram-Negative Bacteria
8.1.4. Gram-Positive Bacteria
8.1.5. Viral Infections
9. Febrile Neutropenia Market – By Diagnostic Methods
9.1. Overview
9.1.1. Segment Share Analysis, By Diagnostic Methods, 2024 & 2032 (%)
9.1.2. Blood Cultures
9.1.3. Bone Marrow Aspiration
9.1.4. Imaging Tests
10. Febrile Neutropenia Market – By Risk Factors
10.1. Overview
10.1.1. Segment Share Analysis, By Etiology, 2024 & 2032 (%)
10.1.2. Transplant-Related Neutropenia
10.1.3. Chemotherapy-Induced Neutropenia
10.1.4. Genetic Disorders
11. Febrile Neutropenia Market – By End User
11.1. Overview
11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
11.1.2. Hospitals
11.1.3. Ambulatory Surgical Centers
11.1.4. Specialty Clinics
11.1.5. Others
12. Febrile Neutropenia Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Febrile Neutropenia Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Febrile Neutropenia Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Febrile Neutropenia Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Febrile Neutropenia Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Febrile Neutropenia Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Febrile Neutropenia Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. Amgen Inc.
13.2.2. Sanofi S.A.
13.2.3. Bayer AG
13.2.4. Biogen Inc.
13.2.5. Ono Pharmaceutical Co., Ltd.
13.2.6. Merck & Co., Inc.
13.2.7. Pfizer Inc.
13.2.8. Teva Pharmaceutical Industries Ltd.
13.2.9. Novartis AG
13.2.10. Johnson & Johnson
13.2.11. AstraZeneca plc
13.2.12. AbbVie Inc.
13.2.13. Takeda Pharmaceutical Company Limited
13.2.14. Celgene Corporation
13.2.15. Roche Holding AG
13.2.16. Bristol-Myers Squibb Company
13.2.17. GlaxoSmithKline plc
13.2.18. Eli Lilly and Company
13.2.19. Gilead Sciences, Inc.
13.2.20. Ipsen S.A.
13.2.21. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FEBRILE NEUTROPENIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Amgen Inc.
- Sanofi S.A.
- Bayer AG
- Biogen Inc.
- Ono Pharmaceutical Co., Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Johnson & Johnson
- AstraZeneca plc
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Celgene Corporation
- Roche Holding AG
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Ipsen S.A.
- Others
GLOBAL FEBRILE NEUTROPENIA MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032
- Empirical Antibiotic Therapy
- Supportive Care
- Targeted Antibiotic Therapy
GLOBAL FEBRILE NEUTROPENIA MARKET, BY ETIOLOGY- MARKET ANALYSIS, 2019 - 2032
- Fungal Infections
- Gram-Negative Bacteria
- Gram-Positive Bacteria
- Viral Infections
GLOBAL FEBRILE NEUTROPENIA MARKET, BY DIAGNOSTIC METHODS- MARKET ANALYSIS, 2019 - 2032
- Blood Cultures
- Bone Marrow Aspiration
- Imaging Tests
GLOBAL FEBRILE NEUTROPENIA MARKET, BY RISK FACTORS- MARKET ANALYSIS, 2019 - 2032
- Transplant-Related Neutropenia
- Chemotherapy-Induced Neutropenia
- Genetic Disorders
GLOBAL FEBRILE NEUTROPENIA MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Others
GLOBAL FEBRILE NEUTROPENIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
